文献速递造血干细胞移植与细胞治疗血栓与止血

自体诱导多能干细胞来源血小板产品的生产及非临床评价:iPLAT1临床试验

Production and nonclinical evaluation of an autologous iPSC-derived platelet product for the iPLAT1 clinical trial.
PubMed 文献 · Blood Adv · 2022-01-01

供者来源血小板用于治疗或预防血小板减少症患者出血,但约5%或以上患者因针对HLA-I或人血小板抗原(HPA)的同种抗体出现同种免疫性血小板输注无效(allo-PTR)。为日本一例因罕见HPA-1错配导致allo-PTR的再生障碍性贫血患者生产血小板产品,研究者建立了基于良好生产规范(GMP)的体外生产体系,从患者诱导多能干细胞(iPSC)建立永生化巨核祖细胞系(imMKCL),经湍流生物反应器和新药生产iPSC来源血小板(iPSC-PLTs),并在广泛非临床研究中确认质量、安全性和有效性,包括兔模型止血。

要点

  • 从患者iPSC建立imMKCL并选出合格克隆用于主细胞库,确认安全性包括病原体阴性。
  • 利用湍流生物反应器和 new drugs 从主细胞库生产iPSC-PLTs。
  • 非临床研究确认iPSC-PLTs质量、安全性和有效性,包括兔模型止血。

核心结论

  • 报告了基于GMP生产iPSC-PLTs的完整体系及所需非临床研究,支持在无相容供者的allo-PTR患者中开展首次人体iPLAT1临床试验(使用自体产品)。

研究设计与样本

  • 基于GMP的体外生产体系开发及广泛非临床研究,从患者iPSC建立imMKCL并选出合格克隆用于主细胞库。

主要发现

  • 从主细胞库利用湍流生物反应器和新药生产出iPSC-PLTs。
  • 非临床研究确认iPSC-PLTs的质量、安全性和有效性,包括兔模型止血。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Donor-derived platelets are used to treat or prevent hemorrhage in patients with thrombocytopenia. However, ∼5% or more of these patients are complicated with alloimmune platelet transfusion refractoriness (allo-PTR) due to alloantibodies against HLA-I or human platelet antigens (HPA). In these cases, platelets from compatible donors are necessary, but it is difficult to find such donors for patients with rare HLA-I or HPA. To produce platelet products for patients with aplastic anemia with allo-PTR due to rare HPA-1 mismatch in Japan, we developed an ex vivo good manufacturing process (GMP)-based production system for an induced pluripotent stem cell-derived platelet product (iPSC-PLTs). Immortalized megakaryocyte progenitor cell lines (imMKCLs) were established from patient iPSCs, and a competent imMKCL clone was selected for the master cell bank (MCB) and confirmed for safety, including negativity of pathogens. From this MCB, iPSC-PLTs were produced using turbulent flow bioreactors and new drugs. In extensive nonclinical studies, iPSC-PLTs were confirmed for quality, safety, and efficacy, including hemostasis in a rabbit model. This report presents a complete system for the GMP-based production of iPSC-PLTs and the required nonclinical studies and thus supports the iPLAT1 study, the first-in-human clinical trial of iPSC-PLTs in a patient with allo-PTR and no compatible donor using the autologous product. It also serves as a comprehensive reference for the development of widely applicable allogeneic iPSC-PLTs and other cell products that use iPSC-derived progenitor cells as MCB.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Sugimoto N, Nakamura S, Shimizu S, et al. Production and nonclinical evaluation of an autologous iPSC-derived platelet product for the iPLAT1 clinical trial. Blood Adv. 2022. PMID: 36149941. doi:10.1182/bloodadvances.2022008512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。